Md. Perloff et al., Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes, BIOCH PHARM, 57(11), 1999, pp. 1227-1232
P-Glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) share common substrate
s and expression properties, but the relationship of mdr1 deficiency to CYP
3A-mediated metabolism and protein, expression is not established. The in v
itro kinetic parameters of CYP3A-mediated metabolism of midazolam (MDZ), tr
iazolam (TRZ), and dexamethasone (DEX) were studied in liver microsomes fro
m three mdr1a(-/-) mice, one mdr1a/b(-/-) mouse, and mdr1a/b(+/+) controls.
The kinetic profiles of CYP3A-mediated MDZ 4-hydroxylation were not signif
icantly different between mdr1-deficient animals and controls. Overall mean
(+/- SEM, N = 8) values were: V-max, 0.74 +/- 0.05 nmol/min/mg protein; K-
m, 28.2 +/- 2.7 mu M; and estimated intrinsic clearance, 0.026 +/- 0.003 mL
/min/mg protein. Likewise, rates of formation of alpha-OH- and 4-OH-TRZ (fr
om 500 mu M TRZ), and of DEX metabolites sensitive to ketoconazole inhibiti
on, M1 and M5 (from 20 mu M DEX), did not differ between mdr1-deficient and
control animals. Immunoquantified microsomal CYP3A protein levels in mdr1a
(-/-), mdr1/a/b(-/-), and mdr1a/b(-/-) mice were not different, with overal
l mean immunoreactive protein levels of 2.68 +/- 0.09 pmol/mu g protein. Al
though CYP3A and P-gp share aspects of activity and expression, disruption
of the mdr1 genes does not affect CYP3A-mediated metabolism or protein expr
ession in the mouse. BIOCHEM PHARMACOL 57;11:1227-1232, 1999. (C) 1999 Else
vier Science Inc.